The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation

• Published in: PLoS pathogens Vol. 13; no. 12; p. e1006784
• Main Authors: Long, Quanxin, Yan, Ran, Hu, Jieli, Cai, Dawei, Mitra, Bidisha, Kim, Elena S, Marchetti, Alexander, Zhang, Hu, Wang, Soujuan, Liu, Yuanjie, Huang, Ailong, Guo, Haitao
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 29-12-2017; Public Library of Science (PLoS)
• Subjects: Biology and life sciences; Research and Analysis Methods
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1006784

Hepadnavirus covalently closed circular (ccc) DNA is the bona fide viral transcription template, which plays a pivotal role in viral infection and persistence. Upon infection, the non-replicative cccDNA is converted from the incoming and de novo synthesized viral genomic relaxed circular (rc) DNA, presumably through employment of the host cell's DNA repair mechanisms in the nucleus. The conversion of rcDNA into cccDNA requires preparation of the extremities at the nick/gap regions of rcDNA for strand ligation. After screening 107 cellular DNA repair genes, we herein report that the cellular DNA ligase (LIG) 1 and 3 play a critical role in cccDNA formation. Ligase inhibitors or functional knock down/out of LIG1/3 significantly reduced cccDNA production in an in vitro cccDNA formation assay, and in cccDNA-producing cells without direct effect on viral core DNA replication. In addition, transcomplementation of LIG1/3 in the corresponding knock-out or knock-down cells was able to restore cccDNA formation. Furthermore, LIG4, a component in non-homologous end joining DNA repair apparatus, was found to be responsible for cccDNA formation from the viral double stranded linear (dsl) DNA, but not rcDNA. In conclusion, we demonstrate that hepadnaviruses utilize the whole spectrum of host DNA ligases for cccDNA formation, which sheds light on a coherent molecular pathway of cccDNA biosynthesis, as well as the development of novel antiviral strategies for treatment of hepatitis B.